Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Immunovant (IMVT)
NASDAQ:IMVT
Holding IMVT?
Track your performance easily
IMVT Stock Chart & Stats
Day’s Range― - ―
52-Week Range$22.41 - $41.38
Previous CloseN/A
Volume171.97K
Average Volume (3M)1.00M
Market Cap
$3.49B
Enterprise Value$3.70B
Total Cash (Recent Filing)$325.00K
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)―
Beta0.68
Next Earnings
Feb 12, 2025EPS Estimate
-0.75Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.21
Shares Outstanding146,784,640
10 Day Avg. Volume1,052,451
30 Day Avg. Volume1,004,619
Standard Deviation0.23
R-Squared0.02
Alpha0.02
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-10.10
P/FCF Ratio0.00
Enterprise Value/Market Cap1.06
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda-10.87
Forecast
1Y Price Target
$50.17Price Target Upside110.80% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering7
Immunovant News
PremiumCompany Announcements
Immunovant Progresses in Autoimmune Therapy Development
PremiumCompany Announcements
Immunovant Raises $450 Million Through Share Purchase Agreement
Bulls Say, Bears Say
Bulls Say
Graves' Disease TreatmentIMVT-1402 has a high potential for success in treating Graves' disease, where a significant percentage of patients are inadequately treated.
Pivotal Trials And DevelopmentImmunovant is on track to initiate potential registrational trials in multiple indications, including Graves' Disease and rheumatoid arthritis.
Rheumatoid Arthritis Market PositionImmunovant has a headstart in the rheumatoid arthritis market with its pivotal trial, ahead of competitors like Biohaven that are only in Phase 1.
Bears Say
Market SentimentThe short interest for the company stands at 20.3% of the float.
Product Launch DelaysThe TED launch is delayed to 2027 due to data push impacted by enrollment competition from other trials.
Project DelaysThere is a small timeline push for the Ph3 TED readout to the second half of 2025 due to slower than expected enrollment, which has resulted in a slight tweak in the price objective.
---
Ownership Overview
2.73% Insiders
15.46% Mutual Funds
24.73% Other Institutional Investors
49.22% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
IMVT FAQ
What was Immunovant’s price range in the past 12 months?
Immunovant lowest stock price was $22.41 and its highest was $41.38 in the past 12 months.
What is Immunovant’s market cap?
Immunovant’s market cap is $3.49B.
When is Immunovant’s upcoming earnings report date?
Immunovant’s upcoming earnings report date is Feb 12, 2025 which is in 25 days.
How were Immunovant’s earnings last quarter?
Immunovant released its earnings results on Nov 07, 2024. The company reported -$0.74 earnings per share for the quarter, missing the consensus estimate of -$0.6 by -$0.14.
Is Immunovant overvalued?
According to Wall Street analysts Immunovant’s price is currently Undervalued.
Does Immunovant pay dividends?
Immunovant does not currently pay dividends.
What is Immunovant’s EPS estimate?
Immunovant’s EPS estimate is -0.75.
How many shares outstanding does Immunovant have?
Immunovant has 146,784,640 shares outstanding.
What happened to Immunovant’s price movement after its last earnings report?
Immunovant reported an EPS of -$0.74 in its last earnings report, missing expectations of -$0.6. Following the earnings report the stock price went down -4.742%.
Which hedge fund is a major shareholder of Immunovant?
Currently, no hedge funds are holding shares in IMVT
---
Immunovant Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$50.17 (110.80% Upside)
$50.17 (110.80% Upside)
Blogger Sentiment
Bullish
IMVT Sentiment 75%
Sector Average 71%
Sector Average 71%
Hedge Fund Trend
Increased
By 815.5K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $335.1M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 3.8%
Last 30 Days ▲ 5.1%
Last 30 Days ▲ 5.1%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-43.66%
12-Months-Change
Fundamentals
Return on Equity
-92.17%
Trailing 12-Months
Asset Growth
76.57%
Trailing 12-Months
Company Description
Immunovant
Immunovant, Inc. is a clinical-stage biopharmaceutical company. It focuses on enabling normal lives for patients with autoimmune diseases. The company was founded in 2018 and is headquartered in New York, NY.
---
IMVT Stock 12 Month Forecast
Average Price Target
$50.17
▲(110.80% Upside)
Technical Analysis
Iovance Biotherapeutics
―
Allogene Therapeutics
―
AnaptysBio
―
Kura Oncology
―
Zymeworks
―
Meiragtx Holdings
―
Best Analysts Covering IMVT
1 Year
1 Year Success Rate
10/18 ratings generated profit
1 Year Average Return
+85.06%
reiterated a buy rating 2 months ago
Copying Thomas Smith's trades and holding each position for 1 Year would result in 55.56% of your transactions generating a profit, with an average return of +85.06% per trade.
---